A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Development, Expansion, and In vivo Monitoring of Human NK Cells from Human Embryonic Stem Cells (hESCs) and Induced Pluripotent Stem Cells (iPSCs)

16.1K views

DOI:

10.3791/50337

April 23rd, 2013

* These authors contributed equally

In This Article

Summary

This protocol describes the development, expansion, and in vivo imaging of NK cells derived from hESCs and iPSCs.

Abstract

We present a method for deriving natural killer (NK) cells from undifferentiated hESCs and iPSCs using a feeder-free approach. This method gives rise to high levels of NK cells after 4 weeks culture and can undergo further 2-log expansion with artificial antigen presenting cells. hESC- and iPSC-derived NK cells developed in this system have a mature phenotype and function. The production of large numbers of genetically modifiable NK cells is applicable for both basic mechanistic as well as anti-tumor studies. Expression of firefly luciferase in hESC-derived NK cells allows a non-invasive approach to follow NK cell engraftment, distribution, and function. We also describe a dual-imaging scheme that allows separate monitoring of two different cell populations to more distinctly characterize their interactions in vivo. This method of derivation, expansion, and dual in vivo imaging provides a reliable approach for producing NK cells and their evaluation which is necessary to improve current NK cell adoptive therapies.

Introduction

Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are undifferentiated, pluripotent cells capable of unlimited self-renewal and multi-lineage differentiation. hESCs have been successfully differentiated into mature and functional subsets of each germ layer, including cells of the hematopoietic system1-3. Natural killer (NK) cells are lymphocytes of the innate immune system that can be derived from hESCs by formation of embryoid bodies (EBs)4,5 or co-culture with stromal cell lines1,2,6-8. NK cells possess anti-viral and anti-tumor capabilities and have the potential to be effective against a broad range of m....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Adapting hESCs or iPSCs in TrypLE for Spin EB Cultures

  1. The initial dissociation with TrypLE works best if the ES/iPS colonies from the collagenase-passaged cultures are relatively small. The starting ES/iPS populations should be cells passed no longer than 4-5 days previous. 4-5 days before initiation of TrypLE passage, pass ES cells at a density that will allow the cells to be ~70% confluent in 4 days time. Use regular ES media for culture of TrypLE-passaged ES cells. Here, we are using hESCs stably modified with a luciferase reporter construct (Materials Table). The protocol also works with iPSCs, using unmodified iPSCs for comparison....

Access restricted. Please log in or start a trial to view this content.

Results

The generation of hematopoietic progenitor cells using the spin EB approach allows for optimal NK cell development from hESCs and iPSCs. As demonstrated in Figure 2, day 11 spin EBs contain high percentages of progenitor cells expressing CD34, CD45, CD43, and CD31. High levels of CD34 and CD45 allows direct transfer to NK conditions without need for sorting or supporting stromal cells. If there is suboptimal spin EB differentiation, it is recommended that stromal cells such as EL08-1D2 are used in the se.......

Access restricted. Please log in or start a trial to view this content.

Discussion

hESCs are an ideal platform to study diverse cell types and hold remarkable potential for clinical translation. We use a defined, spin EB approach to differentiate hESC/iPSCs to hematopoietic progenitor cells. The spin EB approach has yielded consistent derivation of hematopoietic progenitor cells and differentiation to NK cells; yet, variation still exists in differentiation efficiency across cell lines and may need to be modified for generation of other hematopoietic cell lineages. While comparable results can be obtai.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

This work was supported by NIH/NHLBI R01-HL77923 (D.S.K.) and by NIH MSTP grant T32 GM008244 (D.A.K.), Stem Cell Biology Training Grant T32 (D.A.K.)(T32HD060536), Undergraduate Research Opportunities Program (UROP) Grant, University of Minnesota (A.M.B), the Leukemia Research Fund of the University of Minnesota Cancer Center, and the William L and Blanche Hughes Foundation.

Acknowledgements

The authors would like to thank Melinda Hexum for initiation of the spin EB protocol within our lab. We would like to thank other members of the lab, including Laura E. Bendzick, Michael Lepley, and Zhenya Ni for their technical assistance with this work. The authors would also like to thank Brad Taylor at Caliper Life Sciences for his expert technical advice.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Materials
Media
BPEL media for Spin EB generation
Iscove's Modified Dulbecco's Medium (IMDM)Fisher ScientificSH3022801
F-12 Nutrient Mixture w/ Glutamax IInvitrogen31765035
Bovine Serum Albumin (BSA)Sigma-AldrichA3311Commercially available BSA can be cytotoxic to ES cells. Deionizing the solution can reduce the potential for cytotoxicity.
Poly(vinyl alcohol)Sigma-AldrichP8136
Linoleic AcidSigma-AldrichL1012
Linolenic AcidSigma-AldrichL2376
Synthechol 500X solutionSigma-AldrichS5442
a-monothioglycerol (a-MTG)Sigma-AldrichS5442
Protein-free hybridoma mix IIInvitrogen12040077
Ascorbic Acid 2-phosphateSigma-AldrichA8960
Glutamax IInvitrogen35050061
Insulin, Transferrin, Selenium 100X solution (ITS)Invitrogen41400-045
Pen-StrepInvitrogen15140122
NK Differentiation Media
Dubecco's Modified Eagle Medium (DMEM)Invitrogen11965-118
F-12 MediaInvitrogenCX30315
15% Human AB serumValley BiomedHP1022HI
5 ng/ml Sodium SeleniteSigma-AldrichS5261
50 uM ethanolamineSigma-AldrichE9508
20 ng/ml ascorbic acidSigma-AldrichA8960
25 uM 2-mercapt–thanol (BME)Gibco21985
2 mM L-glutamineGibcoCX30310
1% Pen-StrepInvitrogen15140122
Cytokines
(all cytokines used fresh from frozen aliquots)
SCFPeproTech, Inc.300-0740 ng/ml in BPEL media; 20 ng/ml in NK medium). As noted by the Elefanty protocol, and as we discovered with a bad lot of BMP4, there can be lot differences with cytokines in regards to hematopoietic differentiation.Especially if buying cytokines in bulk, obtain a sample of the lot to test prior to purchase. Compare head-to-head with old lot.
rhBMP-4R & D Systems314-BP20 ng/ml in BPEL media
rhVEGFR&D Systems293-VE20 ng/ml in BPEL media
IL-2PeproTech, Inc.200-021 x 105 U/ml given to mice after NK cell injection; 50 U/ml used in NK cell expansion protocol
IL-15PeproTech, Inc.200-1510 ng/ml given to mice after NK cell injection (first 7 days only)
IL-3PeproTech, Inc.200-035 ng/ml in NK media
IL-7PeproTech, Inc.200-0720 ng/ml in NK media
Flt-3-LigandPeproTech, Inc.300-1910 ng/ml in NK media
In vivo Imaging
D-Luciferin Sodium SaltGold BioTechnologyLucna-500
TurboFP650 plasmidEvrogen, Moscow, RussiaFP731Subcloned into a Sleeping Beauty transposon based plasmid driven by the mCAGs promoter. Cells were then sorted on their expression of turboFP650 by FACS. Cells and plasmids can be obtained from our lab.
Equipment
IVIS Spectrum Imaging SystemCaliper Life Sciences
Cells
Membrane bound IL-21 expressing artificial antigen presenting cellsfigure-materials-1 MD Anderson, Houston, TXcontact: Dean A. Lee. http://www.jove.com/video/2540/expansion-purification-functional-assessment-human-peripheral-blood
Firefly luciferase expressing hESCsUniversity of Minnesota, Minneapolis, MNcontact: Dan S. Kaufman . H9 cells modified with a Sleeping Beauty transposon based method (references 13 and 14). Expression of firefly luciferase is driven by the mCAGGS promoter. Following the firefly luciferase gene is an IRES element at the 5' end of a GFP:zeocin fusion construct.
TurboFP650 expressing K562 cellsUniversity of Minnesota, Minneapolis, MNcontact: Dan S. Kaufman. Description under plasmid comments section

Materials Table.

References

  1. Keller, G. M. In vitro differentiation of embryonic stem cells. Current Opinion in Cell Biology. 7, 862-869 (1995).
  2. Kaufman, D. S. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proceedings of the Nationa....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

hESC DifferentiationiPSC DifferentiationFeeder Free ApproachNK Cell ExpansionDual In Vivo ImagingBioluminescent ImagingFlow CytometryChromium Release AssayArtificial Antigen Presenting Cells